NASDAQ:BLPH Bellerophon Therapeutics - BLPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.73 -0.09 (-4.95%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.73▼$1.8550-Day Range$0.67▼$2.5852-Week Range$0.67▼$3.50Volume10,363 shsAverage Volume2.63 million shsMarket Capitalization$16.52 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Bellerophon Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside998.3% Upside$19.00 Price TargetShort InterestHealthy2.72% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.03) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector752nd out of 1,029 stocksPharmaceutical Preparations Industry371st out of 504 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Bellerophon Therapeutics has a forecasted upside of 998.3% from its current price of $1.73.Amount of Analyst CoverageBellerophon Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.72% of the float of Bellerophon Therapeutics has been sold short.Short Interest Ratio / Days to CoverBellerophon Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bellerophon Therapeutics has recently increased by 1,450.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBellerophon Therapeutics has received a 77.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for pulmonary hearth diseases" and "Clinical research services for hypertension" products. See details.Environmental SustainabilityThe Environmental Impact score for Bellerophon Therapeutics is -0.86. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Bellerophon Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 2 people have added Bellerophon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of Bellerophon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.36% of the stock of Bellerophon Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bellerophon Therapeutics are expected to grow in the coming year, from ($2.03) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bellerophon Therapeutics (NASDAQ:BLPH) StockBellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.Read More Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.comJanuary 18, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 6, 2023 | benzinga.comHow Is The Market Feeling About Bellerophon Therapeutics?January 6, 2023 | benzinga.comShort Volatility Alert: Bellerophon TherapeuticsJanuary 6, 2023 | finance.yahoo.comCompanies Like Bellerophon Therapeutics (NASDAQ:BLPH) Could Be Quite RiskyJanuary 5, 2023 | finance.yahoo.comBellerophon Therapeutics Shares Gained Over 200% TodayNovember 14, 2022 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 14, 2022 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsSeptember 28, 2022 | finance.yahoo.comBellerophon (BLPH) Receives FDA Acceptance to Reduce Study SizeSeptember 27, 2022 | finance.yahoo.comWhy Are Bellerophon Shares Jumping Today?September 27, 2022 | marketwatch.comBellerophon Therapeutics Shares Rise After FDA Accepts Trial ProposalSeptember 27, 2022 | finance.yahoo.comBellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseAugust 15, 2022 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial ResultsMay 16, 2022 | nasdaq.comBuying Power of Bitcoin vs. Bellerophon Therapeutics at New 52-Week HighMay 12, 2022 | finance.yahoo.comBellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International ConferenceMay 11, 2022 | seekingalpha.comBellerophon Therapeutics GAAP EPS of -$0.59 misses by $0.04May 11, 2022 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial ResultsMarch 31, 2022 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial ResultsMarch 2, 2022 | finance.yahoo.comWe Think Bellerophon Therapeutics (NASDAQ:BLPH) Needs To Drive Business Growth CarefullyJanuary 10, 2022 | finance.yahoo.comBellerophon to Present at the H.C. Wainwright BioConnect 2022 ConferenceDecember 17, 2021 | finance.yahoo.comBellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with SarcoidosisDecember 1, 2021 | finance.yahoo.comBellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 15, 2021 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial ResultsSeptember 7, 2021 | finance.yahoo.comBellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceSeptember 3, 2021 | nasdaq.comWill Bellerophon Therapeutics (NASDAQ:BLPH) Spend Its Cash Wisely?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Company Calendar Last Earnings11/14/2022Today2/07/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$19.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+998.3%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.79% Return on Assets-96.69% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.76Miscellaneous Outstanding Shares9,550,000Free Float7,187,000Market Cap$16.52 million OptionableNot Optionable Beta0.36 Key ExecutivesPeter FernandesChief Executive, Regulatory & Safety OfficerParag Suresh ShahVice President-Business OperationsNicholas LacconaSecretary, Chief Financial & Accounting OfficerMartin DekkerVice President-Engineering & ManufacturingEdwin L. ParsleyChief Medical OfficerKey CompetitorsIterum TherapeuticsNASDAQ:ITRMLandos BiopharmaNASDAQ:LABPNeuroSense TherapeuticsNASDAQ:NRSNAptorum GroupNASDAQ:APMHumanigenNASDAQ:HGENView All CompetitorsInsiders & InstitutionsTelemetry Investments L.L.C.Sold 21,500 shares on 11/17/2022Ownership: 0.497%Vanguard Group Inc.Sold 15,596 shares on 11/15/2022Ownership: 3.616%Renaissance Technologies LLCSold 13,208 shares on 11/14/2022Ownership: 2.055%View All Institutional Transactions BLPH Stock - Frequently Asked Questions What is Bellerophon Therapeutics' stock price forecast for 2023? 0 analysts have issued 1 year price objectives for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they predict the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 998.3% from the stock's current price. View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts. How have BLPH shares performed in 2023? Bellerophon Therapeutics' stock was trading at $0.90 at the start of the year. Since then, BLPH stock has increased by 92.2% and is now trading at $1.73. View the best growth stocks for 2023 here. Are investors shorting Bellerophon Therapeutics? Bellerophon Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 251,100 shares, an increase of 1,450.0% from the December 31st total of 16,200 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.7% of the company's shares are sold short. View Bellerophon Therapeutics' Short Interest. When is Bellerophon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our BLPH earnings forecast. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. When did Bellerophon Therapeutics' stock split? Shares of Bellerophon Therapeutics reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX). When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $1.73. How much money does Bellerophon Therapeutics make? Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $16.52 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com. This page (NASDAQ:BLPH) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.